MGRM: Monogram Announces it has Received an Additional Information Request (AIR) from the FDA Regarding its Recent 510(k) Submission.

Zacks Small Cap Research10-31

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT FDA Response to 510(k) Filing On October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information Request...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480705057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 22:18","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2480705057","market":"us","top_or_hot":-1,"title":"MGRM: Monogram Announces it has Received an Additional Information Request (AIR) from the FDA Regarding its Recent 510(k) Submission.","media":"Zacks Small Cap Research","content":"<div>\n<p>By Thomas Kerr, CFA\n NASDAQ:MGRM\nREAD THE FULL MGRM RESEARCH REPORT\nFDA Response to 510(k) Filing\nOn October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information Request...</p>\n\n<a href=\"https://finance.yahoo.com/news/mgrm-monogram-announces-received-additional-141800097.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MGRM: Monogram Announces it has Received an Additional Information Request (AIR) from the FDA Regarding its Recent 510(k) Submission.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMGRM: Monogram Announces it has Received an Additional Information Request (AIR) from the FDA Regarding its Recent 510(k) Submission.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 22:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mgrm-monogram-announces-received-additional-141800097.html><strong>Zacks Small Cap Research</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Thomas Kerr, CFA\n NASDAQ:MGRM\nREAD THE FULL MGRM RESEARCH REPORT\nFDA Response to 510(k) Filing\nOn October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information Request...</p>\n\n<a href=\"https://finance.yahoo.com/news/mgrm-monogram-announces-received-additional-141800097.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0006061336.USD","symbol_name":"Blackrock US Small and MidCap Opportunities A2 USD","start_time":0,"source_url":"https://finance.yahoo.com/news/mgrm-monogram-announces-received-additional-141800097.html","article_id":"2480705057","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480705057","pubTimestamp":1730384280,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On October 6, 2024, Monogram  announced it had received an Additional Information Request  from the U.S. Food and Drug Administration  on September 30, 2024, regarding its 510 premarket filing submission for the semi-active mBs TKA System.The application was submitted on July 19, 2024, and passed the initial FDA Administrative Review.As Monogram responds to questions and issues raised in the AIR, the company will, in parallel, pursue a submission for its active modality with Outside the United States  clinical data as it continues to work through the AIR for its semi-active system.Conduct OUS live-patient surgery trials and submit clinical trial data to FDA, with clinical trials expected to include 92 total knee replacement procedures with a 3 month clinical follow-up.Monogram has the potential to deliver strong revenue growth and positive earnings over the next 10 years after commercialization of its robotic system and customized press-fit implants. We believe the company can generate","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BK4134":"信息科技咨询与其它服务","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","MGRM":"Monogram Orthopaedics Inc","AIRI":"Air Industries Group","BK4504":"桥水持仓","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SYK":"史赛克","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","ZBH":"齐默巴奥米特控股","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4572":"航空租赁","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","BK4187":"航天航空与国防","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","III":"信息服务","BK4585":"ETF&股票定投概念","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4566":"资本集团","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","BK4082":"医疗保健设备","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0882574055.USD":"富达全球健康医疗A ACC","AIR":"AAR公司","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","SNN":"Smith & Nephew PLC ADS","BK4588":"碎股","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC"},"translate_title":"MGRM：Monogram宣布已收到FDA关于其最近提交的510(k)的附加信息请求(AIR)。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIRI":1,"ZBH":1,"SYK":1,"SNN":1,"MGRM":1,"III":1,"AIR":1},"content_text":"By Thomas Kerr, CFA\n NASDAQ:MGRM\nREAD THE FULL MGRM RESEARCH REPORT\nFDA Response to 510(k) Filing\nOn October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information Request (“AIR”) from the U.S. Food and Drug Administration (“FDA”) on September 30, 2024, regarding its 510(k) premarket filing submission for the semi-active mBôs TKA System.\nThe application was submitted on July 19, 2024, and passed the initial FDA Administrative Review.\nThe FDA informed the Monogram that it had placed the application on hold pending a complete response to the AIR. The FDA has informed the company that it has 180 days from the date of the AIR to provide a complete response to their questions. AIRs from the FDA are very common for complex medical device submissions. \nAs Monogram responds to questions and issues raised in the AIR, the company will, in parallel, pursue a submission for its active modality with Outside the United States (“OUS”) clinical data as it continues to work through the AIR for its semi-active system.\nMilestones\n ➢ Obtain regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals, with Indian government regulatory clearance expected in early late 2024 or Q1 2025.\n ➢ Conduct OUS live-patient surgery trials and submit clinical trial data to FDA, with clinical trials expected to include 92 total knee replacement procedures with a 3 month clinical follow-up.\n ➢ Seek to obtain clearance for the mBôs™ TKA System.\n ➢ Continue exploring domestic relationships.\n ➢ Continue expanding international relationships (the company will be exhibiting at Arab Health in January 2025). \nClosing of Upsized and Oversubscribed $13 Million Public Offering\nThe company closed on its previously announced equity offering on October 1, 2024. The company sold 5,790,479 units, with each unit consisting of one share of Series D Preferred Stock and one common stock purchase warrant. The warrant allows the holder to purchase one share of the company's common stock. The company received gross proceeds of approximately $13.0 million (net proceeds of $11.7 million).\nMonogram intends to use the net proceeds of the offering to fund general corporate and business purposes, operational needs, and various strategic initiatives, including among other things, new technology development and potential acquisitions.\nDividends on the Series D Preferred Stock are payable quarterly in arrears on or about the 15th day of January, April, July and October, beginning on or about October 15, 2024. The first dividend, which is scheduled to be paid on October 15, 2024, will be $0.033 per share of Series D Preferred Stock. \nValuation and Estimates\nMonogram has the potential to deliver strong revenue growth and positive earnings over the next 10 years after commercialization of its robotic system and customized press-fit implants. We believe the company can generate average annual revenue growth in the range of 25%-40% over the next 10 years and improve margins to industry averages over time.\nOur primary valuation tool utilizes a Discounted Cash Flow process. Under the scenario described above, our DCF based valuation target is approximately $6.00 per share. Our target price may be conservative as it utilizes a high discount rate of 15.0% due to the unpredictability of earnings, higher prevailing interest rates, and the timeline of commercialization of the company’s products in the U.S. \nA peer group of companies (NYSE:SYK, NYSE:ZBH, NYSE:SNN) are currently trading at approximately 4.25x sales on average, with the closest robotic competitor being SYK at 6.15x. This would create a relative value in the range of $4.75-$5.00 using Monogram’s estimated 2027 revenues and discounted back. Using Monogram’s closest competitor’s price/sales ratio, a long-term relative target value would be closer to $8.00. \nSUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. \n \nDISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480705057"}